Zydus Cadila Gets First Patch Approval Amid Push Into US

 
• By Aidan Fry

A generic rival to Novartis’ Exelon extended-release treatment for dementia marks Zydus Cadila’s first transdermal patch approval in the US, furthering the Indian firm’s strategy of targeting more complex delivery forms.

Patch
Zydus Cadila has extended its US generics offering with its first approval for a transdermal patch • Source: Shutterstock

More from Products

More from Generics Bulletin